Safety, Tolerability, and Pharmacokinetics of Inhaled Virazole Administered Via Air-Jet Nebulizer in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 12, 2021

Primary Completion Date

July 12, 2021

Study Completion Date

July 12, 2021

Conditions
Healthy
Interventions
DRUG

50 mg/mL Virazole Inhalant Product

50 mg/mL Virazole (10 or 20 ml total volume) aerosolized and administered until solution depleted

DRUG

100 mg/mL Virazole Inhalant Product

100 mg/mL Virazole (10 or 20 ml total volume) aerosolized and administered until solution depleted

DRUG

Placebo

Placebo (10 or 20 ml total volume) aerosolized and administered until solution depleted

Trial Locations (1)

L4W 1A4

Bausch Site 1, Mississauga

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY

NCT05229510 - Safety, Tolerability, and Pharmacokinetics of Inhaled Virazole Administered Via Air-Jet Nebulizer in Healthy Volunteers | Biotech Hunter | Biotech Hunter